<DOC>
	<DOCNO>NCT01803321</DOCNO>
	<brief_summary>This study pilot , ascend dose , multi-center , randomize , double blind , placebo control , pediatric study conduct three phase .</brief_summary>
	<brief_title>Study Evaluate Safety Tolerability Two Doses Rilonacept Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis ( SJIA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Inclusion Criteria include , limited , follow : Patients age 4 less 21 year meet criterion active SJIA Must stable dose nonsteroidal antiinflammatory drug ( NSAIDs ) least 4 week prior screen visit Exclusion Criteria include , limited , follow : Use certain medication prior baseline visit History recurrent infection</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>SJIA</keyword>
</DOC>